Comparison of Clinical Severity Improvement Degree between Acute Thrombotic Stroke Patients with Low and High Matrix Metalloproteinase-9 Levels
Keywords:Acute thrombotic stroke, MMP-9, NIHSS Level
Background: Stroke is a cause of disability and dependency in both humanity and economic. Studies on the association of Matrix metallopeptidase 9 (MMP-9) levels with improved clinical severity are currently limited. Objectives: To determine the improvement of clinical severity in acute thrombotic stroke patients with high and low MMP-9 levels. Methods: Patients acute thrombotic stroke were grouped into low and high MMP-9 levels. MMP-9 levels were considered low when <840 ng/mL and high when ?840 ng/mL. Clinical severity improvement was assessed using the ?NIHSS scale. Results: Eighty subjects were enrolled that consists of clinical severity improved patients with lower MMP9 (37.9%) that higher than high MMP-9 (21.6%). This difference was not statistically significant (p = 0.115). Conclusion: There was no difference in clinical severity improvement in patients with acute thrombotic stroke with low MMP-9 levels in blood serum compared to high MMP-9 levels.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions